Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

September 17, 2025

Study Completion Date

September 17, 2025

Conditions

Metabolic SyndromeHypertensionOverweight and Obesity

Interventions

DRUG

Eplerenone

mineralocorticoid receptor antagonist and potassium-sparing diuretic

DRUG

Chlorthalidone with potassium chloride

potassium-wasting diuretic with potassium chloride

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT04519164 - Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity | Biotech Hunter | Biotech Hunter